Creso welcomes LGC Capital into strategic alliance
One of the most expansive (yet, least utilised) market niches to be found in the world today is medicinal cannabis. Medicinal cannabis products are becoming increasingly more accessible in parallel to government regulations softening across the developed world.
As you would expect, the liberation of previously cloistered markets, is breeding entrepreneurship and innovative methods of making medical cannabis a commercial morsel.
Creso Pharma (ASX:CPH) and TSX-listed LGC Capital (TSX-V.LG), have jointly announced the formation of a strategic alliance intended to create a vertically-integrated cannabis company with a global footprint spanning cultivation, IP generation and commercially-viable innovative products.
The agreement paves the way for the two companies to form a mutually-beneficial alliance, to develop innovative pharmaceutical solutions addressing the growing demand for cannabis and hemp-derived therapeutics, cosmetics, nutraceuticals and lifestyle products.
It is early stages in this agreement thus far so interested investors should seek professional financial advice if considering this stock for their portfolio.
Currently, the ‘nutraceuticals’ market is estimated to be worth around US$200 billion annually, and expected to reach US$205 billion by the end of 2017.
By focusing on unique and innovative product delivery mechanisms, Creso Pharma is developing cannabis and hemp therapeutic products, manufactured to the highest pharmaceutical GMP standard and delivered to the highest quality levels across the supply chain.
CPH has said that it will update the market with full details, terms and conditions of the agreement early next year. One key factor that may be play a part in supporting CPH’s internal development as well as attracting further investment capital to CPH, is the influence of David Lenigas, the current Founder and Co-Chairman of LGC .
Mr. Lenigas is a renowned Australian-based investor with past involvement in Artemis Resources (ASX:ARV), a Resources company that made instant market headlines for its recent gold discovery in WA (and also strategically backed by Lenigas’ investment company LGC).
Accompanying Creso’s alliance with LGC Capital, David Lenigas said, “Creso operates under the highest GMP Swiss standards and all of its products are manufactured, quality controlled and certified in Switzerland. Creso’s team consists of globally-recognised pharma professionals and this alliance between Creso and LGC is a terrific development for both companies.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Longhou Capital Markets Pty Ltd (AFSL No. 292464). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.